EP2365804A2 - Modification of amyloid-beta load in non-brain tissue - Google Patents
Modification of amyloid-beta load in non-brain tissueInfo
- Publication number
- EP2365804A2 EP2365804A2 EP09761084A EP09761084A EP2365804A2 EP 2365804 A2 EP2365804 A2 EP 2365804A2 EP 09761084 A EP09761084 A EP 09761084A EP 09761084 A EP09761084 A EP 09761084A EP 2365804 A2 EP2365804 A2 EP 2365804A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- brain
- compound
- disorder
- subject
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract description 8
- 230000004048 modification Effects 0.000 title description 7
- 238000012986 modification Methods 0.000 title description 7
- 210000005013 brain tissue Anatomy 0.000 title description 5
- 210000004556 brain Anatomy 0.000 claims abstract description 146
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 145
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims abstract description 124
- 230000000694 effects Effects 0.000 claims abstract description 84
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 80
- 230000002093 peripheral effect Effects 0.000 claims abstract description 61
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims abstract description 44
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 230000005764 inhibitory process Effects 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 210000004185 liver Anatomy 0.000 claims description 81
- 238000004519 manufacturing process Methods 0.000 claims description 81
- 239000003814 drug Substances 0.000 claims description 70
- 230000014509 gene expression Effects 0.000 claims description 68
- 230000008499 blood brain barrier function Effects 0.000 claims description 52
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 52
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 51
- -1 naproxyn Chemical compound 0.000 claims description 46
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 41
- 229960002411 imatinib Drugs 0.000 claims description 35
- 238000009825 accumulation Methods 0.000 claims description 31
- 101150096148 Psen2 gene Proteins 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108010036908 Presenilin-2 Proteins 0.000 claims description 21
- 102000012419 Presenilin-2 Human genes 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 20
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 20
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 20
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 20
- 102100032216 Calcium and integrin-binding protein 1 Human genes 0.000 claims description 19
- 101710103933 Calcium and integrin-binding protein 1 Proteins 0.000 claims description 19
- 230000002068 genetic effect Effects 0.000 claims description 17
- 230000002452 interceptive effect Effects 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 238000005192 partition Methods 0.000 claims description 15
- 229940125782 compound 2 Drugs 0.000 claims description 13
- 102000016936 neugrin Human genes 0.000 claims description 13
- 108010028893 neugrin Proteins 0.000 claims description 13
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 claims description 12
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 claims description 12
- PSXOKXJMVRSARX-SCSAIBSYSA-N 5-chloro-n-[(2s)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide Chemical compound FC(F)(F)C(C(F)(F)F)[C@@H](CO)NS(=O)(=O)C1=CC=C(Cl)S1 PSXOKXJMVRSARX-SCSAIBSYSA-N 0.000 claims description 12
- 239000002876 beta blocker Substances 0.000 claims description 12
- 229940097320 beta blocking agent Drugs 0.000 claims description 12
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 101150081739 NGRN gene Proteins 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 229940125904 compound 1 Drugs 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 7
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 7
- 239000005541 ACE inhibitor Substances 0.000 claims description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002160 alpha blocker Substances 0.000 claims description 6
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
- 229940030600 antihypertensive agent Drugs 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000000480 calcium channel blocker Substances 0.000 claims description 6
- 229930003827 cannabinoid Natural products 0.000 claims description 6
- 239000003557 cannabinoid Substances 0.000 claims description 6
- 229940065144 cannabinoids Drugs 0.000 claims description 6
- 239000002934 diuretic Substances 0.000 claims description 6
- 229940030606 diuretics Drugs 0.000 claims description 6
- 102000015694 estrogen receptors Human genes 0.000 claims description 6
- 108010038795 estrogen receptors Proteins 0.000 claims description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- 229960000905 indomethacin Drugs 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- YWQVBESSYLICRX-UHFFFAOYSA-N n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-pyridinecarboxamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC=CN=C1 YWQVBESSYLICRX-UHFFFAOYSA-N 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 238000010855 neuropsychological testing Methods 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 238000002610 neuroimaging Methods 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 15
- 230000001537 neural effect Effects 0.000 abstract description 13
- 239000012530 fluid Substances 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 description 67
- 210000001519 tissue Anatomy 0.000 description 55
- 229940079593 drug Drugs 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 36
- 201000010099 disease Diseases 0.000 description 36
- 108020004999 messenger RNA Proteins 0.000 description 29
- 230000001225 therapeutic effect Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000000349 chromosome Anatomy 0.000 description 15
- 210000003169 central nervous system Anatomy 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 14
- 229940080856 gleevec Drugs 0.000 description 13
- 229960003685 imatinib mesylate Drugs 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000007082 Aβ accumulation Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108700019146 Transgenes Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 239000003607 modifier Substances 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108091092195 Intron Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102000003780 Clusterin Human genes 0.000 description 6
- 108090000197 Clusterin Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010036933 Presenilin-1 Proteins 0.000 description 6
- 102000012412 Presenilin-1 Human genes 0.000 description 6
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 5
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 5
- 102000005650 Notch Receptors Human genes 0.000 description 5
- 108010070047 Notch Receptors Proteins 0.000 description 5
- 108010050254 Presenilins Proteins 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000015499 Presenilins Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 239000003540 gamma secretase inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000583474 Homo sapiens Phosphatidylinositol-binding clathrin assembly protein Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101710159527 Maturation protein A Proteins 0.000 description 3
- 101710091157 Maturation protein A2 Proteins 0.000 description 3
- 108700011325 Modifier Genes Proteins 0.000 description 3
- 102100031014 Phosphatidylinositol-binding clathrin assembly protein Human genes 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007278 cognition impairment Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 210000001009 nucleus accumben Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241001323319 Psen Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000007791 alzheimer disease like pathology Effects 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 102000046783 human APP Human genes 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- PUOAETJYKQITMO-LANLRWRYSA-N (3e)-1-[(1s)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one Chemical compound C1([C@H](C)N2CCC\C(C2=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC=C(F)C=C1 PUOAETJYKQITMO-LANLRWRYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102000019049 Zinc Finger E-box Binding Homeobox 2 Human genes 0.000 description 1
- 108010012198 Zinc Finger E-box Binding Homeobox 2 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 101150089041 aph-1 gene Proteins 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940092923 livalo Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- BQQYXPHRXIZMDM-UHFFFAOYSA-N n-Demethylated piperazine Chemical class C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C(C=C1)=CC=C1CN1CCNCC1 BQQYXPHRXIZMDM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 102000046701 nicastrin Human genes 0.000 description 1
- 108700022821 nicastrin Proteins 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- XMFCOYRWYYXZMY-UHFFFAOYSA-N sulmazole Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=NC=CC=C2N1 XMFCOYRWYYXZMY-UHFFFAOYSA-N 0.000 description 1
- 229950006153 sulmazole Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 108091006105 transcriptional corepressors Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- the present invention relates to methods and compositions for modulating levels of amyloid- ⁇ peptide (A ⁇ ) exhibited by non-neural (i. e. , peripheral) cells, fluids, or tissues.
- the invention also relates to modulation of brain A ⁇ levels via selective modulation (e.g., inhibition) of ⁇ -secretase activity in peripheral tissues.
- the invention further relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to a neural A ⁇ -related disorder, by peripherally administering a compound that results in the modulation of ⁇ -secretase, either directly or indirectly.
- the invention also relates to the use of modulators of ⁇ - secretase activity via peripheral administration to prevent, treat or ameliorate the symptoms of Alzheimer's disease.
- Amyloid- ⁇ (A ⁇ ) peptides are metabolites of the Alzheimer's disease- associated precursor protein, ⁇ -amyloid precursor protein (APP), and are believed to be the major pathological determinants of Alzheimer's disease (AD).
- AD is a neurodegenerative disorder characterized by the age-dependent deposition of A ⁇ within vulnerable regions of the brain, particularly the frontal cortex and hippocampus (Terry RD. J Geriatr Psychiatry Neural 19: 125-128, 2006).
- a ⁇ has a pathogenic effect, leading to progressive neuronal loss that causes deterioration of the ability of those brain regions to orchestrate both higher order and basic neural processes. As the deterioration worsens, the affected individual faces dementia and a worsening quality of life, and eventually the condition is fatal (Brookmeyer R, Johnson E,
- AD Alzheimer's disease
- Some of the genes whose protein products affect AD risk have been identified. For example, there are three common variants of the gene that encodes the serum protein Apolipoprotein E, called e2, e3 and e4. Individuals who inherit an e4-encoding allele are at higher risk than average for AD and tend to develop disease at earlier times than individuals with no e4 alleles. Those who inherit e4 alleles from both parents are at even higher risk for early-onset AD, while individuals with e2 alleles are at very low risk, developing the disease later in life than the average if at all (Cedazo-Minguez A. J Cell MoI Med. 11 : 1227-38, 2007). Traumatic brain injury and repetitive brain trauma have also been found to accelerate brain A ⁇ deposition and cognitive impairment. Uryu et al. J. Neurosci. 22 (2): 446 (2002).
- AD Most if not all AD is considered to have some genetic component that is linked to the risk threshold for each individual.
- some forms of human AD are particularly highly heritable. These heritable forms are caused by rare mutations in single genes that encode proteins that are associated with this neurodegenerative disorder and that play central roles in the initiation of the disease process. Mutations in these genes can be inherited or can arise sporadically.
- APP Amyloid Precursor Protein
- APP is a membrane protein whose biochemical function is at present unknown. It is known that APP is a substrate for proteolysis by several endogenous proteases, and that proteolysis liberates fragments having various structures. Two of the protease activities are referred to as ⁇ -secretase and ⁇ - secretase.
- ⁇ -secretase Proteolysis of APP by ⁇ -secretase generates a fragment that can subsequently be cleaved by ⁇ -secretase at multiple sites to produce A ⁇ peptides
- ⁇ - secretase is complex of several proteins (including presenilin 1 and presenilin X), and cleavage of APP by ⁇ -secretase produces multiple isoforms of A ⁇ , which range from 37 to 43 amino acid residues (see, e.g., Steiner H, Fluhrer R, Haass C, J Biol Chem. 2008 JuI 23).
- a 42-residue form of A ⁇ is thought to be the most pathogenic (Wolfe MS. Biochemistry 45:7931-7939, 2006).
- the 42-residue A ⁇ fragment forms oligomeric structures, which, in addition to forming the plaques that deposit in the AD-affected brain, are thought to cause cognitive deficits (Barten DM, Albright CF. MoI Neurobiol 37:171-186, 2008).
- Variations in APP that predispose to AD cluster in the vicinity of the proteolytic cleavage sites, affecting the rate at which pathogenic A ⁇ fragments are generated, their stability, and their ability to form oligomers (Selkoe DJ. Physiol Rev 81 :741— 766, 2001).
- Individuals inheriting such APP variations usually show signs of AD in their 50s, whereas sporadic AD is not common until individuals reach their 70s (Waring SC, Rosenberg RN. Arch Neurol. 65:329-34, 2008).
- ⁇ -secretase activity is reduced 80% in cultured cells derived from embryos genetically deleted for presenilin 1. All ⁇ -secretase activity is lost in cells lacking both presenilin 1 and presenilin 2.
- Peptidomimetic inhibitors of ⁇ -secretase activity can be crosslinked to presenilins 1 and 2, suggesting that these proteins are catalytic subunits for the cleavage.
- ⁇ -secretase activity isolated from cells chromatographs as a large complex >1M daltons.
- a third enzyme, ⁇ -secretase cleaves the precursor protein between the ⁇ - and ⁇ -cleavage sites, precluding A ⁇ production and releasing an approximately 3 kDa peptide known as P3, which is non-pathological. Both ⁇ - and ⁇ -secretase cleavage also result in soluble, secreted terminal fragments of APP, known as sAPP ⁇ and sAPP ⁇ , respectively.
- the sAPP ⁇ fragment has been suggested to be neuroprotective. As a consequence of these genetic observations and considerable biochemical and neuroanatomical experimentation, the model has emerged that biochemical events that increase the production and accumulation of A ⁇ , particularly A ⁇ -42, accelerate the onset and progression of AD.
- mice that are transgenic for AD-predisposing APP and that additionally carry an inactivating knockout mutation in the ⁇ -secretase gene exhibit nearly complete reductions of A ⁇ in the brain (Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Nat Neurosci 4:231-232, 2001).
- mice nonetheless exhibit cognitive deficits, premature death, and hypomyelination (Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Eur J Neurosci 23:251-260, 2006; Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF.
- ⁇ -secretase inhibitors have also been investigated. Brain-penetrant ⁇ -secretase inhibitors have been shown to reduce A ⁇ synthesis and reduce cognitive deficits in mouse models of AD (Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF. Drugs R D 7:87-97, 2006). However, ⁇ -secretase has targets in addition to APP (Pollack SJ, Lewis H. Curr Opin Investig Drugs 6:35-47, 2005), one of which is the Notch family of transmembrane receptors.
- This class of compounds includes the tyrosine kinase inhibitor imatinib mesylate (STI-571, trade name GLEEVEC) and the related compound, 6-(2,6-dichlorophenyl)-8-methyl-2-(methylsulfanylphenyl-amino)-8H- pyrido[2,3- ⁇ T]pyrimidin-7-one, referred to as inhibitor 2 (Netzer WJ, et ⁇ /.,_Proc Natl Acad Sci U S A. 100:12444-12449, 2003).
- STI-571 trade name GLEEVEC
- 6-(2,6-dichlorophenyl)-8-methyl-2-(methylsulfanylphenyl-amino)-8H- pyrido[2,3- ⁇ T]pyrimidin-7-one referred to as inhibitor 2 (Netzer WJ, et ⁇ /.,_Proc Natl Acad Sci U S A. 100:12444-12449, 2003).
- STI-571 is presently approved for treatment of myelogenous leukemia and gastrointestinal stromal tumors. STI-571 potently reduces the production of A ⁇ , both in APP-transfected neuroblastoma cells and in cell-free extracts of transfected cells, via a mechanism that does not require the AbI tyrosine kinase, one of the important targets of this drug in leukemia cells (Netzer, supra).
- STI-571 and a related compound called “Inhibitor 2" were found to reduce production of A ⁇ in cultures of primary neurons prepared from cerebral cortex of embryonic day 18 rats (Netzer, supra), indicating that these drugs affect proteolytic processing of proteins from both endogenous and transfected APP genes.
- STI-571 according to the product literature for GLEEVEC, is administered orally.
- the drug has been investigated for its effect on A ⁇ accumulation in brain and the drug has been shown to have poor penetration of the blood-brain barrier.
- the cerebral spinal fluid (CSF) level of the drug was 92-fold lower than the level in the blood (Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S._Br J Haematol. 119:106-108, 2002). Therefore, its utility in unmodified form as a potential therapeutic for AD has been dismissed (Netzer, supra).
- the present invention relates to methods of treating, preventing or monitoring a brain A ⁇ disorder, by testing and/or treating peripheral (non-brain, non-CNS) tissues.
- the peripheral tissue comprises liver, while in other embodiments, the peripheral tissue comprises blood/and or serum.
- the present invention comprises assessing a subject for the presence of AD or predisposition to AD, peripherally administering a compound that modulates accumulation or production of A ⁇ , and assessing said subject for AD or progression of AD.
- the present invention provides methods, compositions and processes related to treatment or prevention of AD by treating the liver of a subject.
- the present invention relates to altering A ⁇ production, processing, accumulation or transport in the liver of a subject by direct inhibition of production (e.g., by inhibition of expression of APP), or by modulating a factor that in turn modulates production, processing, accumulation or transport of A ⁇ in liver.
- Such factors include but are not limited to ⁇ -secretase, presenilin 1, presenilin 2, ApoE, calmyrin, neugrin, inositol 1,4,5-trisphosphate receptor (InsP3R) or Smad-interacting protein-1 (SIPl, encoded by Zfhxlb), clusterin (encoded by CLU, also known as ApoJ), phosphoinositol-binding clatherin assembly protein (encoded by PICALM), complement component receptor 1 (encoded by CRl), and modulators thereof.
- the invention encompasses the treatment or prevention of AD by modulation of any factor that, when modulated, influences - either directly (e.g., by acting on APP production or processing) or indirectly (e.g.
- the production of A ⁇ in liver of a subject by acting on a factor that, in turn, acts on a factor that acts on APP), the production of A ⁇ in liver of a subject.
- the invention is not limited by the nature of the modulation, or the identity or number of factors acted upon to modulate A ⁇ in the liver of a subject.
- the present invention provides methods of treating a subject diagnosed with as having a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder, comprising peripherally administering a compound that modulates production of A ⁇ in a peripheral tissue.
- the compound inhibits production of A ⁇ .
- a peripherally administered compound has a partition coefficient of less than 2.0, more preferably less than 1.5, and still more preferably less than about 1.0.
- the compound does not substantially cross the blood-brain barrier.
- the present invention provides methods of treating a subject for a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder in a subject, comprising peripherally administering a compound that modulates expression of a gene in a peripheral tissue of said subject.
- modulation of said expression of said gene results in modulation of A ⁇ production or accumulation in said peripheral tissue.
- the peripheral tissue is the liver of a subject.
- the present invention encompasses any method of influencing the production of A ⁇ in liver, including but not limited to altering expression and/or processing of APP.
- the present invention provides methods comprising peripherally administering a compound that modulates expression of one or more of Psen 1, Apo E, InsP3R, Psen2, APP, Cibl, Ngrn, Zfhxlb, CLU (also known as ApoJ), PICALM, and CRl genes.
- the methods of the present invention comprises peripherally administering a compound that modulates the activity of one or more of presenilin 2, calmyrin, neugrin, Zfhxlb, clusterin, phosphoinositol-binding clatherin assembly protein, complement component receptor 1 or APP expression or activity.
- one or more of these genes or activities is modulated in the liver of a subject.
- modulation comprises inhibition of expression or activity, while in some embodiments, modulation comprises stimulation of expression or activity.
- the present invention comprises a method, e.g., of treating a brain A ⁇ disorder, comprising the steps of assessing a subject for the presence of a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder, peripherally administering a compound that modulates production of A ⁇ , wherein the compound does not substantially penetrate the blood brain barrier, and assessing the subject for a brain A ⁇ disorder or progression of a brain A ⁇ disorder. It is further contemplated that, in some embodiments, the results of the assessment pre and post treatment are compared, to determine, e.g., the effect of treatment on the status of the brain A ⁇ disorder (e.g., to determine an effect on onset or rate of development or relief of diseases). Modulation of production of A ⁇ is not limited to any particular means or pathway of modulation. Modulation of production may include, e.g., alteration (e.g., reduction) of expression of APP, or alteration of processing of APP into A ⁇ .
- the invention comprises the steps of assessing a subject for the presence of a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder, peripherally administering a compound that modulates accumulation of A ⁇ , wherein the compound does not substantially penetrate the blood brain barrier, and assessing the subject for a brain A ⁇ disorder or progression of a brain A ⁇ disorder.
- Modulation of accumulation of A ⁇ is not limited to any particular means. Modulation of accumulation may include, e.g., decreasing production of A ⁇ and/or increasing degradation or clearance of A ⁇ , or alteration of A ⁇ to produce a modified form with different properties (e.g., a non-pathogenic form).
- the modulation of production and/or accumulation of A ⁇ comprises a modulator of a ⁇ -secretase activity, while in some preferred embodiments, the compound comprises an inhibitor of a ⁇ -secretase activity. It is further contemplated that in some embodiments of the invention, the modulation of production and/or accumulation of A ⁇ , the compound administered comprises a modulator of Presenilin 2. In some preferred embodiments, the compound comprises an inhibitor of Presenilin 2. In some embodiments, the compound comprises a modulator of cleavage of amyloid precursor protein, while in some embodiments, the compound comprises an inhibitor of cleavage of amyloid precursor protein.
- the compound comprises a composition selected from the group consisting of STI-571, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, and E2012 (Eisei) compound, or a blood-brain barrier impermeable variant thereof.
- the composition has a partition coefficient (e.g. , in an octano I/water system) of less than 2.0, more preferably less than 1.5, and still more preferably less than about 1.0.
- the compound does not substantially cross the blood-brain barrier.
- the compound comprises an interfering oligonucleotide, while in preferred embodiments, the compound comprises interfering RNA.
- the interfering RNA is selected from the group consisting of siRNA, shRNA and miRNA.
- the interfering RNA comprises an interfering RNA directed toward amyloid precursor protein RNA, while in other embodiments, the interfering RNA comprises an interfering RNA directed toward Presenilin 2 RNA.
- the compound further comprises a known therapeutic agent for treating, ameliorating, or reducing risk or severity of a brain A ⁇ -related disorder.
- the known therapeutic agent is selected from the group consisting of cannabinoids, dimebom, prednisone, ibuprofen, naproxyn, indomethacin; statins, selective estrogen receptor molecules, antihypertensives, alpha-blockers, beta-blockers, alpha-beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and antioxidants.
- the peripheral administration of said compound in the method of the present invention is not limited to any particular route.
- the peripherally administering comprises orally administering.
- the assessing comprises a mental status evaluation. In some preferred embodiments, the assessing comprises one or more of neuropsychological testing and brain imaging.
- the present invention provides a method of assessing risk of or presence of a brain A ⁇ disorder in a subject, comprising determining a level of A ⁇ in a peripheral tissue of said subject.
- the invention provides a method of monitoring a brain A ⁇ disorder in a subject, comprising determining a level of A ⁇ in a peripheral tissue of said subject.
- the peripheral tissue is blood, while in some embodiments, the peripheral tissue is serum.
- monitoring comprises measuring A ⁇ in said peripheral tissue at a plurality of time points.
- the brain A ⁇ disorder is Alzheimer's disease.
- the present invention provides methods of monitoring a brain A ⁇ disorder in a subject comprising analysis of expression or activity of a gene product in peripheral tissue of said subject.
- the gene product is from a gene selected from the group consisting of Psen2, APP, Cibl, Ngrn, and Zfhxlb.
- the present invention provides a method, comprising the steps of assessing a subject for the presence of a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder, and peripherally administering a compound that inhibits the transport of peripheral A ⁇ across the blood brain barrier, wherein said compound is not an anti-A ⁇ antibody.
- the brain A ⁇ disorder is Alzheimer's disease.
- the present invention provides a method of identifying a genetic target for treatment of a brain A ⁇ disorder, comprising comparing a liver gene expression profile of offspring from a first parent who has or who is predisposed to said A ⁇ disorder and a second parent having reduced susceptibility to said A ⁇ disorder, to identify a heritable genetic marker having a level of expression in liver, wherein increased or decreased expression of said heritable genetic marker in liver of said offspring relative to the level of expression in the liver of said first parent correlates with inheritance of said genetic marker from said second parent.
- the present invention comprises a compound selected from the group consisting STI-571, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, and E2012 compound, or a blood-brain barrier impermeable variant thereof, for use in the modulation of production of A ⁇ in peripheral tissue of a subject having or predisposed to developing a A ⁇ disorder.
- the A ⁇ disorder is a brain A ⁇ disorder.
- the compound has a partition coefficient of less than 2.0, more preferably less than 1.5, and still more preferably less than about 1.0. In particularly preferred embodiments, the compound does not substantially cross the blood-brain barrier.
- the present invention provides a compound selected from the group consisting STI-571, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, and E2012 compound, or a blood-brain barrier impermeable variant thereof, for use in the modulation (e.g., inhibition) of production of A ⁇ in liver of a subject having or predisposed to developing an A ⁇ disorder.
- the A ⁇ disorder is a brain A ⁇ disorder.
- the compound has a partition coefficient of less than 2.0, more preferably less than 1.5, and still more preferably less than about 1.0. In particularly preferred embodiments, the compound does not substantially cross the blood-brain barrier.
- the invention relates to use of a compound selected from the group consisting, imatinib (STI-571), WGB-BC-15, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, and E2012 compound, a blood-brain barrier impermeable variant thereof, and/or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the modulation of production of A ⁇ in a peripheral tissue of a subject having or predisposed to developing a brain A ⁇ disorder
- the medicament is formulated for oral administration.
- the peripheral tissue comprises liver.
- the compound has a partition coefficient of less than 2.0, preferably less than 1.5, and still more preferably less than about 1.0.
- the compound does not substantially cross the blood-brain barrier.
- the present invention relates to use of imatinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of production of A ⁇ in liver of a subject having or predisposed to developing a brain A ⁇ disorder.
- the invention also provides for the use of the compounds as described above for the manufacture of a medicament comprising a second therapeutic agent for the treatment of a brain A ⁇ disorder.
- a second therapeutic agent is selected from imatinib (STI-571) WGB-BC-15, Compound 1, Compound 2, LY450139, GSI-953, Flurizan, and E2012 compound, a blood-brain barrier impermeable variant thereof, and/or a pharmaceutically acceptable salt thereof.
- the second therapeutic agent comprises one or more agents selected from the group consisting of cannabinoids, dimebom, prednisone, ibuprofen, naproxyn, indomethacin; statins, selective estrogen receptor molecules, antihypertensives, alpha-blockers, beta-blockers, alpha-beta blockers, angiotensin- converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and antioxidants.
- the compound comprises imatinib in the form of the mesylate salt.
- Figure IA shows a graph comparing the amount of Psen2 mRNA in liver samples from subject mice, compared to genotype of the mice at the Psen2 locus.
- Figure IB shows graphs plotting Psen2 locus genotype (B6/B6 or D2/D2) vs. Psen2 mRNA concentration in 6 tissues (arbitrary units) from the up to 89 recombinant inbred (RI) lines. The parental C57 and DBA values are plotted next to those from the RI lines. Some tissues have data from single RI lines that are heterozygous at the Psen2 locus: these are represented on the plots as B6/D2. Data obtained from GeneNetwork.org (J. Wang, R. W. Williams, K.F. Manly KF, Neuroinformatics 1, 299 (2003)).
- liver expression data were initially expressed as the ratio of the liver fluorescence signal to that generated by the reference mRNA sample for each probe. Data were normalized using a robust LOWESS smoothing method that adjusts for non-linearity of signal in the two channels. We then computed the log base 2 of these ratios (median). A value of -1 indicates that expression in liver is roughly 1/2 that in the control; a value of -2 indicates that expression in the liver is roughly 1/4 that in the control, etc. Conversely, a value of +2 indicates that the expression in liver is 4-fold greater in liver. Liver data set from 40 recombinant inbred lines described in by D. Gatti, et al., Hepatology 46, 548 (2007). For other tissues, expression values and alternative normalization methods were as indicated (Wang, supra).
- Figure 2 is a diagram of the chemical structures of STI-571, the mesylate salt GLEEVECTM), STI-571 variant ("WGB-BC-15"), Compound 1 (PD173955, Moasser et al, 1999, Cancer Research 59: 6145-6152; Wisniewski et al., Cancer Research 2002, 62(15):4244-55), and Compound 2 (PD166326; Wisniewski et al, Cancer Research 2002, 62(15):4244-55).
- Figures 3A-3F show the effects of peripherally administered STI-571 on the levels of A ⁇ in plasma and whole brain.
- Wild-type B6 and D2 mice (age 8-12 weeks [A-F]or 15-18 months[G,H]) were administered drug or vehicle twice daily for 7 days by intraperitoneal injection.
- Fig. 1A shows Western blots showing levels of A ⁇ hexamers in plasma from young D2 mice treated with saline vehicle (lanes 1, 2, 9 and 10) or STI-571 at three doses: lanes 3, 4, 11, and 12 show results with 1 mg
- FIG. 3B shows a bar graph quantification of the Western blot images in Fig. 3A.
- Figure 3D shows a bar graph quantification of the Western blot images in Fig. 3C.
- Figure 4 shows a graph comparing the amount of Ngrn mRNA in liver samples from subject mice, compared to the genotype of the mice at the Ngrn locus.
- Figure 5 shows graphs plotting of Cibl (Fig. 5A) or Zfhxlb (Fig 5B) genotype (B6/B6, B6/D2 or D2/D2) vs. calmyrin (Fig. 5A) or Zfhxlb (Fig 5B) mRNA concentration in liver (arbitrary units) for 40 recombinant inbred lines, as in Figure IB.
- the terms “subject” and “patient” are used interchangeably.
- the terms “subject” and “subjects” refer to an animal, preferably a mammal including a non-primate (e.g., a cow, pig, horse, donkey, goat, camel, cat, dog, guinea pig, rat, mouse, sheep) and a primate (e.g., a monkey, such as a cynomolgous monkey, gorilla, chimpanzee, and a human), preferably a human.
- the subject is a subject with Alzheimer's disease (AD).
- AD Alzheimer's disease
- a ⁇ -related disorder or an "A ⁇ disorder” is a disease (e.g., Alzheimer's disease) or a condition (e.g., senile dementia) that involves an aberration or dysregulation of A ⁇ levels.
- An A ⁇ -related disorder includes, but is not limited to AD, brain trauma-related amyloid disorders, Down's syndrome and inclusion body myositis .
- the term "at risk for disease” refers to a subject ⁇ e.g., a human) that is predisposed to experiencing a particular disease.
- This predisposition may be genetic (e.g. , a particular genetic tendency to experience the disease, such as heritable disorders), or due to other factors (e.g., age, weight, environmental conditions, exposures to detrimental compounds present in the environment, etc.).
- factors e.g., age, weight, environmental conditions, exposures to detrimental compounds present in the environment, etc.
- the term "suffering from disease” refers to a subject (e.g., a human) that is experiencing a particular disease or who has been diagnosed has having a particular disease. It is not intended that the present invention be limited to any particular signs or symptoms, nor disease. Thus, it is intended that the present invention encompasses subjects that are experiencing any range of disease (e.g., from sub-clinical manifestation to full-blown disease) wherein the subject exhibits at least some of the indicia (e.g., signs and symptoms) associated with the particular disease.
- disease and “pathological condition” are used interchangeably to describe a state, signs, and/or symptoms that are associated with any impairment of the normal state of a living animal or of any of its organs or tissues that interrupts or modifies the performance of normal functions, and may be a response to environmental factors (such as emotional trauma, physical trauma, malnutrition, industrial hazards, or climate), to specific infective agents (such as worms, bacteria, or viruses), to inherent defect of the organism (such as various genetic anomalies, or to combinations of these and other factors.
- environmental factors such as emotional trauma, physical trauma, malnutrition, industrial hazards, or climate
- specific infective agents such as worms, bacteria, or viruses
- inherent defect of the organism such as various genetic anomalies, or to combinations of these and other factors.
- the terms "subject having AD” or “subject displaying signs or symptoms or pathology indicative of AD” or “subjects suspected of displaying signs or symptoms or pathology indicative of AD” refer to a subject that is identified or diagnosed as having or likely to have AD based on known AD signs, symptoms and pathology.
- the terms "subject at risk of displaying pathology indicative of AD” and “subject at risk of AD” refer to a subject identified as being at risk for developing AD.
- AD therapeutic refers to an agent used to treat or prevent AD.
- agents include, but are not limited to, small molecules, drugs, antibodies, pharmaceuticals, and the like.
- cognitive function generally refers to the ability to think, reason, concentrate, or remember. Accordingly, the term “decline in cognitive function” refers to the deterioration of lack of ability to think, reason, concentrate, or remember.
- modulate As used herein, the terms “modulate,” “modulates,” “modulated” or “modulation” shall have their usual meanings, and encompass the meanings of the words “enhance,” “promote,” “increase,” “agonize,” “inhibit,” “decrease” or “antagonize.”
- a modulator of, e.g., an enzymatic activity, such as an activity of ⁇ - secretase may act directly, i.e., by direct interaction with the enzyme having the activity to be modulated, or it may act indirectly, i.e., without direct interaction with the enzyme, but via a pathway that results in modulation of the activity.
- assessing a subject for AD refers to performing one or more tests to determine, e.g., the presence or progression of AD in a subject, or the risk of development of AD in a subject. Assessing a subject for AD and/or to distinguishing Alzheimer's disease from other causes of memory loss, may comprise evaluating one or more of the following:
- Medical history comprising assessing a subject's general health and past medical problems, problems a subject may have in carrying out daily activities 2.
- Basic medical tests comprising, e.g., blood tests to rule out other potential causes of the dementia, such as thyroid disorders or vitamin deficiencies.
- Neuropsychological testing comprising more extensive assessment of memory, problem-solving abilities, attention spans, counting skills and language.
- Brain scans or imaging using, e.g., computerized tomography (CT magnetic resonance imaging (MRI); and a positron emission tomography
- CT magnetic resonance imaging (MRI) CT magnetic resonance imaging (MRI)
- MRI positron emission tomography
- an "agonist” is any compound that acts directly or indirectly on a molecule to produce a pharmacological effect
- an “antagonist” is any compound that acts directly or indirectly on a molecule to reduce a pharmacological effect.
- sample and “specimen” are used in their broadest sense and encompass samples or specimens obtained from any source.
- sample is used to refer to biological samples obtained from animals (including humans), and encompasses fluids, solids, tissues, and gases.
- biological samples include neural tissue (e.g., brain tissue) cerebrospinal fluid (CSF), serous fluid, urine, saliva, blood, and blood products such as plasma, serum and the like.
- neural tissue e.g., brain tissue
- CSF cerebrospinal fluid
- serous fluid e.g., urine
- saliva saliva
- blood products such as plasma, serum and the like.
- blood-brain barrier refers a structure in the central nervous system (CNS) that restricts the passage of various chemical substances and microscopic objects (e.g. bacteria) between the bloodstream and the neural tissue.
- CNS central nervous system
- directional references to "inside” and “outside” the blood-brain barrier refer to things on the brain/neural tissue side of blood-brain barrier, or the non-brain/neural side of the blood-brain barrier, respectively.
- blood-brain barrier impermeable variant refers to a variant of a compound having reduced ability to penetrate the blood-brain barrier when administered peripherally to a subject, compare to the penetrability of a parent or reference compound, such that, e.g., the variant does not substantially penetrate the blood-brain barrier of the subject to whom it is administered.
- the ability of a compound to cross the blood-brain barrier may be characterized any of a number of methods known in the art, e.g.
- Methods of determining or estimating brain/CNS uptake of drugs include in vivo methods (e.g., intravenous or carotid injection followed by brain sampling or imaging), in vitro methods using, e.g., isolated brain microvessels or cell culture models, and computational (in silico) prediction methods, typically based on factors such as molecular weight and lipophilicity. See, for example, U. Bickel, NeuroRx. 2005 January; 2(1): 15-26, which is incorporated herein by reference, for a review and comparison of methods of measuring drug transport across the blood-brain barrier.
- the lipophilicity/hydrophilicity of a compound are generally associated with the rate and extent of entry of a compound into the brain.
- the lipophilicity/hydrophilicity of a drug is often represented as a partition coefficient representing the behavior of a drug when partitioned in an immiscible organic/aqueous solvent system.
- An 1-octano I/water partition system has been used extensively in assessing the capability of compounds to cross the blood-brain barrier.
- log P The 1-octano I/water partition coefficient, "log P,” has been in long standing use as a descriptor of lipophilicity, and computer algorithms providing calculated log P values, like Clog P and Mlog P, often closely match experimentally measured values (within about 0.3 log units; Bickel, supra%_
- the distribution coefficients i.e., log P values at a defined pH (typically the physiological plasma pH of 7.4) are used.
- log P and pKa are known
- log D log distribution coefficient
- Log D at pH 7.4 is often quoted to give an indication of the lipophilicity of a drug at the pH of blood plasma. Hansch and coworkers have determined that drugs with a log P of about 2 will generally find ready entry into the central nervous system (Hansch et al, 1987, J.
- the partition coefficient (log P) of imatinib mesylate has been calculated to be 1.198 and 1.267 at 25 and 37 0 C, respectively (Velpandian, et al., Journal of
- peripheral and "periphera” as used in reference to a location in or on, or a tissue of a subject refer to all locations and tissues of the subject that are outside of the blood-brain barrier.
- the phrase "does not substantially cross the blood brain barrier” or “does not substantially penetrate the blood brain barrier” relates to material or compounds, e.g., GLEEVEC imatinib mesylate (STI-571) that, if administered in a peripheral tissue or taken orally, either remain absent from a CNS sampling (e.g., in brain tissue, cerebrospinal fluid) altogether, or are present in the CNS sampling at a small percentage of the concentration found in the peripheral tissue, e.g., less than about 10%, preferably less than about 5%, and more preferably less than about 2% of the concentration found in peripheral tissues.
- GLEEVEC imatinib mesylate STI-571
- STI-571 GLEEVEC imatinib mesylate
- GLEEVEC/STI-571 has poor penetration of the blood-brain barrier, as shown in a STI-571 -treated leukemia patient whose cerebral spinal fluid (CSF) level of the drug was 92-fold lower than in the blood (Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Br J Haematol. 119:106-108, 2002).
- CSF cerebral spinal fluid
- imatinib mesylate does not substantially penetrate the blood brain barrier.
- the term "effective amount” refers to the amount (e.g., of a composition comprising a modulator of ⁇ -secretase activity of the present invention) sufficient to produce a selected effect.
- An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
- a "sufficient amount" of a compound, or “an amount of a compound sufficient to " refers to an amount that contains at least the minimum amount necessary to achieve the intended result. Such an amount can routinely be determined by one of skill in the art based on data from studies using methods of analysis such as those disclosed herein.
- the term "about” means within 10 to 15%, preferably within 5 to 10%.
- the terms “manage,” “managing” and “management” refer to the beneficial effects that a subject derives from a compound, such as a compound that lowers A ⁇ levels exhibited by a cell or tissue, which does not result in a cure of the disease.
- a subject is administered one or more such agents to "manage” a disorder so as to prevent or slow the progression or worsening of the disorder.
- the terms “prevent”, “preventing” and “prevention” refer to the impedition of the recurrence or onset of an A ⁇ -related disorder or one or more symptoms of a A ⁇ -related disorder in a subject.
- a “protocol” includes dosing schedules and dosing regimens.
- the protocols herein are methods of use and include prophylactic and therapeutic protocols.
- the terms “administration” and “administering” refer to the act of giving a drug, prodrug, or other agent, or therapeutic treatment (e.g., compositions of the present invention) to a subject (e.g., a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs).
- Exemplary routes of administration to the human body can be through the eyes (ophthalmic), mouth (oral), skin (topical or transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g., intravenously, subcutaneous Iy, intratumorally, intraperitoneally, etc.) and the like.
- injection e.g., intravenously, subcutaneous Iy, intratumorally, intraperitoneally, etc.
- co-administration refers to the administration of at least two agent(s) (e.g., compositions comprising STI-571 and one or more other agents - e.g. , an A ⁇ -related disease therapeutic) or therapies to a subject.
- the co-administration of two or more agents or therapies is concurrent.
- a first agent/therapy is administered prior to a second agent/therapy.
- formulations and/or routes of administration of the various agents or therapies used may vary. The appropriate dosage for co-administration can be readily determined by one skilled in the art.
- agents or therapies when agents or therapies are coadministered, the respective agents or therapies are administered at lower dosages than appropriate for their administration alone.
- co-administration is especially desirable in embodiments where the co-administration of the agents or therapies lowers the requisite dosage of a potentially harmful (e.g., toxic) agent(s), and/or when co-administration of two or more agents results in sensitization of a subject to beneficial effects of one of the agents via co-administration of the other agent.
- the terms “treat” and “treating” includes administering therapy to prevent, cure, or alleviate/prevent the symptoms associated with, a specific disorder, disease, injury or condition.
- treatment encompasses the improvement and/or reversal of the symptoms of disease (e.g., an A ⁇ -related disease, such as Alzheimer's disease).
- a compound that causes an improvement in any parameter associated with disease when used in the screening methods of the instant invention may thereby be identified as a therapeutic compound.
- treatment refers to both therapeutic treatment and prophylactic or preventative measures.
- those who may benefit from treatment with compositions and methods of the present invention include those already with a disease and/or disorder (e.g. , an A ⁇ -related disease, or symptoms or pathologies consistent with an A ⁇ -related disease) as well as those in which a disease and/or disorder is to be prevented (e.g., using a prophylactic treatment of the present invention).
- a compound refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function.
- a compound may be a single composition (e.g., a pure preparation of a chemical) or it may be a composition comprising a plurality of chemicals (e.g., one or more effective agents and one or more inert agents).
- a compound may comprise both known and potential therapeutic compositions.
- a compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- a "known therapeutic" compound or agent includes a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to have a therapeutic effect in a treatment.
- a known therapeutic compound is not limited to a compound having a particular level of effectiveness in the treatment or prevention of a disease (e.g. , an A ⁇ -related disease), and includes, e.g., compounds for which data suggests that there is some beneficial effect and little or no negative effect (e.g., compounds that are generally recognized as safe, such as food extracts and nutraceutical compounds).
- known therapeutic agents for treating, ameliorating, or reducing risk or severity of A ⁇ -related diseases e.g.
- Alzheimer's disease when used alone or in combination with other compounds or therapies include, but are not limited to cannabinoids (see, e.g., Ramirez, et al, The Journal of Neuroscience, February 23, 2005, 25(8): 1904-1913); dimebom (see, e.g., RS Doody, et al., The Lancet 372:207-215 (2008); anti- inflammitory agents such as prednisone (a steroid) and non-steroidal antiinflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxyn, indomethacin; cholesterol-lowering and/or heart protective drugs such as statins, e.g., atorvastatin (LIPITOR®), cerivastatin (BAYCOL®), fluvastatin (e.g., LESCOL®), mevastatin, pravastatin (e.g.
- statins e.g., atorvastatin (LIPITOR®), ceriva
- SERMs Selective estrogen receptor molecules
- antihypertensives including alpha-blockers, beta-blockers, alpha-beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs, such as valsartan (e.g., DIOV AN®)), calcium channel blockers, and diuretics (see, e.g., I Hajjar, et al, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:67- 73 (2005)); and antioxidants such as garlic extract, curcumin, melatonin, resveratrol, Ginkgo biloba extract, green tea, vitamin C and vitamin E (SERMs), e.g., raloxifene (EVISTA®); antihypertensives, including alpha-blockers, beta-blockers, alpha-beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs, such as val
- small molecule generally refers to a molecule of less than about 10 kDa molecular weight, including but are not limited to natural or synthetic organic or inorganic compounds, peptides, (poly Nucleotides, (oligo)saccharides and the like. Small molecules specifically include small non- polymeric (i.e., not peptide or polypeptide) organic and inorganic molecules.
- extract and like terms refers to a process of separating and/or purifying one or more components from their natural source, or when used as a noun, refers to the composition produced by such a process.
- kits refers to any delivery system for delivering materials.
- delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents and/or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another.
- enclosures e.g., boxes
- fragmented kit refers to delivery systems comprising two or more separate containers that each contains a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately.
- a first container may contain an enzyme for use in an assay, while a second container contains standards for comparison to test compounds.
- fragment kit is intended to encompass kits containing Analyte Specific Reagents (ASR' s) regulated under section 520(e) of the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the term "fragmented kit.”
- a “combined kit” refers to a delivery system containing all of the components of a reaction assay in a single container (e.g., in a single box housing each of the desired components).
- kit includes both fragmented and combined kits.
- the term "toxic” refers to any detrimental or harmful effects on a subject, a cell, or a tissue as compared to the same cell or tissue prior to the administration of the toxicant.
- the term “pharmaceutically purified” refers to a composition of sufficient purity or quality of preparation for pharmaceutical use.
- the term "purified” refers to a treatment of a starting composition to remove at least one other component (e.g. , another component from a starting composition (e.g., plant or animal tissue, an environmental sample etc.), a contaminant, a synthesis precursor, or a byproduct, etc.), such that the ratio of the purified component to the removed component is greater than in the starting composition.
- a starting composition e.g., plant or animal tissue, an environmental sample etc.
- a contaminant e.g., a synthesis precursor, or a byproduct, etc.
- composition refers to the combination of an active agent (e.g., composition comprising a modulator of ⁇ - secretase activity) with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
- an active agent e.g., composition comprising a modulator of ⁇ - secretase activity
- compositions that do not substantially produce adverse reactions, e.g., toxic, allergic, or immunological reactions, when administered to a subject.
- the term "pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers including, but not limited to, phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents, any and all solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic and absorption delaying agents, disintrigrants (e.g., potato starch or sodium starch glycolate), and the like.
- the compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants. (See e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. (1975), incorporated herein by reference).
- the term "pharmaceutically acceptable salt” refers to any salt (e.g., obtained by reaction with an acid or a base) of a compound of the present invention that is physiologically tolerated in the target subject (e.g., a mammalian subject, and/or in vivo or ex vivo, cells, tissues, or organs).
- Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is Ci_ 4 alkyl, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- W is Ci_ 4 alkyl
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosy
- salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W is a Ci_ 4 alkyl group), and the like.
- a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W is a Ci_ 4 alkyl group), and the like.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non- pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- a medicament composition comprises a form selected from the group consisting of powder, solution, emulsion, micelle, liposome, gel, and paste form.
- a medicament composition comprises a tablet or a filled capsule, wherein said tablet or filled capsule optionally comprises an enteric coating material.
- excipient refers to an inactive ingredient (i.e., not pharmaceutically active) added to a preparation of an active ingredient.
- gene refers to a nucleic acid (e.g., DNA) sequence that comprises coding sequences necessary for the production of a polypeptide, precursor, or RNA (e.g., rRNA, tRNA).
- the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, immunogenicity, etc.) of the full-length or fragment are retained.
- the term also encompasses the coding region of a structural gene and the sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb or more on either end such that the gene corresponds to the length of the full-length mRNA. Sequences located 5' of the coding region and present on the mRNA are referred to as 5' non-translated sequences. Sequences located 3' or downstream of the coding region and present on the mRNA are referred to as 3' non-translated sequences.
- the term "gene” encompasses both cDNA and genomic forms of a gene.
- a genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed "introns” or “intervening regions” or “intervening sequences.”
- Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript.
- mRNA messenger RNA
- RNA expression and “expression” refer to the process of converting genetic information encoded in a gene into RNA (e.g., mRNA, rRNA, tRNA, or snRNA) through “transcription” of the gene (i.e., via the enzymatic action of an RNA polymerase), and, for protein encoding genes, into protein through “translation” of mRNA.
- Gene expression can be regulated at many stages in the process.
- Up-regulation “ or “activation” refer to regulation that increases and/or enhances the production of gene expression products (e.g. , RNA or protein), while “down-regulation” or “repression” refer to regulation that decrease production.
- Molecules e.g. , transcription factors
- activators and "repressors,” respectively.
- genomic forms of a gene may also include sequences located on both the 5' and 3' end of the sequences that are present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5 ' or 3' to the non-translated sequences present on the mRNA transcript).
- the 5' flanking region may contain regulatory sequences such as promoters and enhancers that control or influence the transcription of the gene.
- the 3' flanking region may contain sequences that direct the termination of transcription, post-transcriptional cleavage and polyadenylation.
- wild-type refers to a gene or gene product isolated from a naturally occurring source.
- a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal” or “wild-type” form of the gene.
- modified or mutant refers to a gene or gene product that displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally occurring mutants can be isolated; these are identified by the fact that they have altered characteristics (including altered nucleic acid sequences) when compared to the wild-type gene or gene product.
- nucleic acid molecule encoding As used herein, the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.
- the term "eukaryote” refers to organisms distinguishable from “prokaryotes.” It is intended that the term encompass all organisms with cells that exhibit the usual characteristics of eukaryotes, such as the presence of a true nucleus bounded by a nuclear membrane, within which lie the chromosomes, the presence of membrane-bound organelles, and other characteristics commonly observed in eukaryotic organisms. Thus, the term includes, but is not limited to such organisms as fungi, protozoa, and animals (e.g., humans).
- the term “in vitro” refers to an artificial environment and to processes or reactions that occur within an artificial environment. In vitro environments can consist of, but are not limited to, test tubes and cell culture.
- test compound refers to the natural environment (e.g., an animal or a cell) and to processes or reaction that occur within a natural environment.
- test compound and “candidate compound” refer to any chemical entity, pharmaceutical, drug, and the like that is a candidate for use to treat or prevent a disease, illness, sickness, or disorder of bodily function (e.g., cognitive function, amyloid-associated disorder, circulation, hypertension, heart disease, etc.).
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- a "functional" molecule is a molecule in a form in which it exhibits a property by which it is characterized.
- a functional enzyme is one which exhibits the characteristic catalytic activity by which the enzyme is characterized.
- antisense oligonucleotide refers to a nucleic acid, e.g., an RNA or DNA segment, that is complementary to the sequence of a target RNA (or fragment thereof).
- target RNA is an mRNA expressed by a cell.
- interfering oligonucleotide relates to an oligonucleotide capable of inhibiting the function of a target gene product, regardless of the mechanism of inhibition.
- interfering oligonucleotides include but are not limited to antisense oligonucleotides, aptamers, microRNAs (miRNAs), short interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs)
- miRNAs microRNAs
- siRNAs short interfering RNAs
- shRNAs short hairpin RNAs
- Short interfering RNAs typically consist of double-stranded RNA molecules, generally 19-22 nt,, while short hairpin RNA, consists of palindromic sequences connected by loop sequences generally 19-29 nt.
- interfering oligonucleotides are well known to those of skill in the art, and include but are not limited to chemical synthesis, recombinant DNA techniques or generation from larger precursor molecule using enzymatic cleavage, e.g., by Dicer enzymes.
- antibody refers to an immunoglobulin or immunoglobulin-derived protein comprising an antigen recognition site.
- Antibodies include but are not limited to natural or recombinant immunoglobulins comprising two heavy chains and two light chains, as well as modified forms, including, e.g., fragment antibodies and single chain antibodies comprising different combinations of portions of the heavy and light chains.
- the term encompasses polyclonal and monoclonal antibodies.
- the present invention is based, in part, on Applicants' surprising discoveries that modulation of A ⁇ expression or accumulation in peripheral tissues, e.g., in liver, provides therapeutic effect in A ⁇ -linked diseases of the brain, e.g., Alzheimer's Disease.
- the present invention therefore, relates, generally, to methods and compositions for preventing or treating a brain A ⁇ -related disorder, such as AD, via administration of compounds that modulate the production and/or accumulation of A ⁇ in non-neural (i.e., peripheral) cells, fluids, and/or tissues.
- a brain A ⁇ -related disorder such as AD
- amyloid- ⁇ (A ⁇ ) peptides are metabolites of the amyloid precursor protein (APP), and are believed to be the major pathological determinants of Alzheimer's disease (AD).
- APP is proteolyzed by ⁇ and ⁇ -secretase to produce A ⁇ peptides, with a 42-residue form of A ⁇ thought to be the most pathogenic, ⁇ -secretase is needed for healthy brain function and thus is a poor candidate for inhibition as a means of reducing A ⁇ .
- a number of brain-penetrant ⁇ -secretase inhibitors have shown undesirable side-effects as a result of disrupting ⁇ -secretase action on other targets, in particular, the Notch family of transmembrane receptors.
- One class of compounds has been found to reduce A ⁇ production without affecting Notch signaling.
- This class of compounds includes the tyrosine kinase inhibitor imatinib mesylate (STI-571, trade name GLEEVEC) and the related compound, 6-(2,6- dichlorophenyl)-8-methyl-2-(methylsulfanylphenyl-amino)-8H-pyrido[2,3- J]pyrimidin-7-one, referred to as inhibitor 2 (Netzer WJ, et al, Proc Natl Acad Sci U S A. 100:12444-12449, 2003).
- this class of compounds has been dismissed as a treatment of brain A ⁇ disorders because it does not cross the blood-brain barrier and is thus prohibitively difficult to deliver to brain tissue.
- the present invention provides methods, compositions and processes related to treatment or prevention of AD by treating the liver of a subject.
- the present invention relates to altering A ⁇ production, processing, accumulation or transport in the liver of a subject by direct inhibition of production (e.g., by inhibition of expression of APP), or by modulating a factor that in turn modulates production, processing, accumulation or transport of A ⁇ in liver.
- the inhibition is through the use of compounds that do not substantially cross the blood-brain barrier.
- compositions and method for treatment comprise the use of a STI-571 or a pharmaceutically acceptable salt thereof, administered peripherally, e.g., orally.
- Imatinib is the generic name [International Non-proprietary Name] for the compound 4-(4-methylpiperazin- l-ylmethyl)-N-[4-methyl-3-(4-pyridin-3- yl)pyrimidin-2-ylamino)phenyl]-benzamide of the following formula I:
- STI-571 generally refers to the mesylate salt of imatinib, and has been approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
- imatinib in the treatment of breast cancer is described in WO 2004/032925.
- Imatinib, its manufacture, its pharmaceutically acceptable salts, e.g. acid addition salts, and its protein kinase inhibiting properties are described in U.S. Patent No. 5,521,184, which is hereby incorporated by reference.
- Imatinib corresponds to 4-(4-methylpiperazin-l-ylmethyl)-N[4-methyl-3-(4-pyridin-3- yl)pyrimidin-2-ylamino)phenyl]-benzamide as either free base or mesylate salt.
- the preparation of imatinib and the use thereof are described in Example 21 of European patent application EP-A-O 564 409, which is hereby incorporated by reference.
- peripheral administration is not limited to any particular route of administration, in some preferred embodiments, administration is oral.
- the present invention comprises use of STI-571 in the preparation of an orally administered medicament for the treatment or prevention of a brain A ⁇ disorder.
- the orally administered form comprises a tablet, while in some embodiments, an orally administered form comprises a capsule.
- the present invention comprises preparation of a tablet or capsule comprising an effective amount of imatinib to reduce A ⁇ levels in brain.
- a capsule or tablet may comprise 100 to 1000 mg of an active agent ⁇ e.g., imatinib or a derivative thereof).
- a tablet or capsule may comprise 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mgs, or any convenient dosage amount in between ⁇ e.g., 125 mgs, 150 mgs, 175 mgs, 225 mgs, 250 mgs . . . 975 mgs, etc.).
- a tablet or capsule is configured to contain a smaller effective dose of imatinib, e.g., 1 to 5 mg ⁇ e.g., 1, 2, 3, 4 or 5 mgs, or a convenient fractional amount thereof), 6 to 10 mgs, 11 to 15 mgs, etc.
- Compositions and formulations for oral administration include, for example, powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets wafers, dissolvable strips, and tablets. Thickeners, flavoring agents, diluents, emulsif ⁇ ers, dispersing aids or binders may be desirable.
- a tablet or capsule (or other form of peripheral administration) is configured to deliver a dose of, or an amount equivalent to any whole integer mg amount between 1 and 1000 mg (e.g., 1, 2, 3, 4, ,5, etc.), or any fractional mg amount between 1 and 1000 mg.
- a formulation may comprise, e.g., a capsule filled with a mixture of the composition:
- Imatinim mesylate (STI-571) 119.5 mgs (corresponding to 100 mg imatinib free base
- a capsule or tablet comprises an enteric coating.
- enteric coating generally refers to a coating that substantially prevents release of a medication before it reaches the small intestine. While not limiting the invention to any particular mechanism of action, it is understood that most enteric coatings work by presenting a surface that is stable at acidic pH but breaks down rapidly at higher pH.
- compositions and formulations for parenteral administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, carrier compounds and other pharmaceutically acceptable carriers or excipients.
- the pharmaceutical formulations of the present invention which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- imatinib mesylate The pharmacokinetics of imatinib mesylate (GLEEVEC) have been evaluated in studies in healthy subjects and in population pharmacokinetic studies. Imatinib is well absorbed after oral administration, with C max achieved within 2-4 hours post- dose. Mean absolute bioavailability is 98%. Following oral administration in healthy volunteers, the elimination half- lives of imatinib and its major active metabolite, the N-desmethyl derivative, are approximately 18 and 40 hours, respectively. Mean imatinib AUC (Area under the plasma drug concentration versus time curve) increases proportionally with increasing doses ranging from 25 mg-1000 mg.
- CYP3A4 is the major enzyme responsible for metabolism of imatinib.
- Other cytochrome P450 enzymes such as CYP 1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism.
- the main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to the parent imatinib.
- the plasma AUC for this metabolite is about 15% of the AUC for imatinib.
- Elimination is predominately in the feces, mostly as metabolites. Based on the recovery of compound(s) after an oral 14C-labeled dose of imatinib, approximately 81% of the dose was eliminated within 7 days, in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.
- clearance of imatinib in a 50-year-old patient weighing 50 kg is expected to be 8 L/h, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/h.
- the inter-patient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment related toxicity.
- imatinib was reportedly rapidly absorbed after oral administration in pediatric patients, with a Cmax of 2-4 hours. Apparent oral clearance was similar to adult values (11.0 L/hr/m2 in children vs. 10.0 L/hr/m2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hr in adults).
- the present invention is not limited to treatment of the liver with this compound, and provides general methods of treating a subject for a brain A ⁇ disorder or predisposition to a brain A ⁇ disorder in a subject, comprising peripherally administering a compound that modulates expression of a gene in a peripheral tissue of said subject.
- modulation of said expression of said gene results in modulation of A ⁇ production or accumulation in said peripheral tissue.
- the peripheral tissue is the liver of a subject.
- the present invention encompasses any method of influencing the production of A ⁇ in liver, including but not limited to altering expression and/or processing of APP.
- the present invention provides methods comprising peripherally administering a compound that modulates expression of one or more of Psen 1, Apo E, InsP3R, Psen2, APP, Cibl, Ngrn, Zfhxlb, CLU (also known as ApoJ), PICALM, and CRl genes.
- the methods of the present invention comprises peripherally administering a compound that modulates the activity of one or more of presenilin 2, calmyrin, neugrin, Zfhxlb, clusterin, phosphoinositol-binding clatherin assembly protein, complement component receptor 1 or APP expression or activity.
- one or more of these genes or activities is modulated in the liver of a subject.
- modulation comprises inhibition of expression or activity, while in some embodiments, modulation comprises stimulation of expression or activity. Assessing and monitoring brain A ⁇ disorders during peripheral treatment
- the present invention relates to testing for and treatment of AD and AD risk by testing of and administration to peripheral (i.e., non-brain) tissues of a subject.
- peripheral tissues i.e., non-brain tissues
- presenilin 2 expression in the liver and/or in one or more peripheral tissues modifies A ⁇ accumulation, and that reduction of A ⁇ in the periphery is sufficient to modify its deposition in the brain.
- an effective therapeutic or prophylactic treatment for AD that reduces A ⁇ accumulation need not cross the blood-brain barrier and enter the brain.
- Inhibition of Psen2 or ⁇ -secretase activity, or reduction of A ⁇ production or accumulation by other means, outside of the central nervous system finds application in the protection of the brain from A ⁇ - related pathologies.
- Treatment of peripheral tissues has the additional benefit of protecting the brain from any adverse side effects that could occur were the therapeutic to enter the brain.
- the present invention provides methods of tailoring treatments to the biochemical status of a subject or patient. It is contemplated that features of effective doses of one or more of compounds selected for the modulation of A ⁇ in a peripheral tissue may be affected by the particular biochemical circumstances of a subject or patient, including but not limited to the presence of other drugs or medications (e.g. for treatment of an A ⁇ disorder or unrelated conditions), or biochemical changes caused by other circumstances.
- the present invention provides methods comprising monitoring a subject by assessing said subject for a brain A ⁇ disorder or progression of a brain A ⁇ disorder before and after administration of a compound that modulates production of A ⁇ , e.g., in liver. In some embodiments, therapy for a brain A ⁇ disorder is selected, adjusted, or altered accordingly.
- Transgenic mouse models have been developed that recapitulate critical features of human Alzheimer's disease.
- the APP gene carrying some of the variations that are AD-predisposing in humans have been joined to various transcriptional promoters and introduced into the mouse germ line (Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature 373:523-527; Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Proc Natl Acad Sci U S A. 96:3228-3233, 1999; Hsiao K, Chapman P, Nilsen S, Eckman C,
- mice develop A ⁇ deposits, but the timing varies from 3 months to 15 months of age.
- the variables responsible for these age differences include the particular transcriptional promoter chosen, the particular AD-predisposing mutations in the APP gene, the chromosomal site of transgene integration and the mouse background strain on which the transgene is perpetuated (reviewed in Bloom FE, Reilly JF, Redwine JM, Wu CC, Young WG, Morrison JH._Arch Neural. 62:185-187, 2005).
- Rl.40 a human APP transgene carrying the so-called Swedish mutations (K670N, M671L, variations that predispose those humans that inherit this mutated gene to develop early-onset AD) into a mixed C57Bl/6xl29/Sv mouse genetic background.
- Expression of the Rl .40 transgene was driven from the natural human APP promoter. A ⁇ deposits were first detectable in brains of these mice at 14-16 months. Subsequently, the Rl.40 transgene was crossed from its initial background separately into C57B1/6 (B6), DBA/2 (D2) and 129/Sv backgrounds.
- each of these 3 strains was bred to congeneity: 10 or more back-crosses into the same background so that 3 transgenic strains with uniform but distinct backgrounds were created (Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Hum MoI Genet. 12:2949-2956, 2003).
- B6s accumulated more A ⁇ (the pathogenic fragment of APP) as measured by ELISA on brain homogenates and plasma at 21 and 60 days than the other 2 strains, and developed amyloid deposits characteristic of human AD at 13.5 months, while the D2s were protected (no deposits at 2 years).
- Regression analysis correlating the amount of A ⁇ accumulation with the genotypes of the 516 mice allowed 3 modifying loci to be assigned to broad regions centered on the following positions: chromosome 1, 182.049374 Megabases (Mb); chromosome 2, 41.216315 Mb; chromosome 7, 63.680922 Mb.
- the mouse gene encoding presenilin 2, Psen2 is located on chromosome 1 at 182.06371 Megabases, the center of the trait locus interval, suggesting it as a candidate for modifying A ⁇ accumulation and deposit. This is consistent with its function as a component of ⁇ -secretase.
- Psen2 to represent the actual modifier mapped to chromosome 1 by Ryman and colleagues, its activity must vary heritably (in a Mendelian fashion) between B6 and D2 mouse strains, and the Psen2 activity must be greater in B6 mice than D2 mice, because lower ⁇ -secretase activity would be expected to be protective in AD.
- Probe rsl3476267 is located on chromosome 1 at 182.120454 Mb.
- mice were administered STI-571 imatinib mesylate by IP injection over the course of one week and brain and tissue samples removed and A ⁇ protein levels measured by ELISA or Western blot.
- Wild-type C57B1/6 and DBA/2J male mice (age 8-12 weeks) were administered drug or vehicle twice daily for 7 days by intraperitoneal injection.
- the STI- 571 dose prescribed for human cancer patients is 100 mg to 1000 mg. See, for example, Gleevec Prescribing Information 2003 revision T2003-09; Printed in U.S.A. 89019001 (Novartis), incorporated herein by reference.
- mice were sacrificed 12 hr after the last injection. Individual mice were anesthetized with isoflurane and blood samples (100-300ul) taken by cardiac puncture with heparinized syringes. Samples were placed on ice for 30 minutes in the presence of EDTA and then centrifuged for 20 minutes at 16,000xg at 4°C. The plasma fraction was removed and stored at -80 0 C. Brains were removed and frozen rapidly on dry ice and stored at -80 0 C. Detection of mouse A ⁇ i_4o in blood and brain samples was performed by using a commercially available immunoassay kit (Biosource mouse A ⁇ i_4o, Catalog No.
- Mouse brain samples were prepared by homogenizing brain tissue in a polytron in the presence of 5M guanidine HCl and 50 mM Tris HCl, pH 8.0 as described in the assay protocol, (see, e.g., Masliah, E., et al., (2001) ⁇ amyloid peptides enhance ⁇ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. PNAS 98:12245-12250; Johnson- Wood, K, et al.
- brain homogenates were diluted 1 : 10 in a reaction buffer containing Dulbecco's phosphate buffered saline with 5% BSA and 0.03% Tween-20, supplemented with protease inhibitor cocktail (Catalog No. 539131, EMD
- Oligomeric A ⁇ was extracted in the SDS fraction essentially as described (T. Kawarabayashi, et al., Neurosci 21, 372 (2001)).
- samples were subjected to PAGE analysis, transferred to PVDF membranes and the A ⁇ hexamers were visualized using a monoclonal antibody 4G8 directed against mouse A ⁇ (1 :1 ,000; Covance) using the manufacturer's recommended protocol.
- Blots were scanned by densitometry, and then reprobed with an antibody to histone H3 (1 :50,000; Abeam) as a loading and transfer control. Data are depicted as normalized optical density.
- Fig. 3 shows the effects of peripherally administered STI-571 on the levels of A ⁇ in plasma and brain.
- Fig. 3B shows a bar graph quantification of the Western blot images in Fig. 3A.
- Figure 3D shows a bar graph quantification of the Western blot images in Fig. 3C.
- STI-571 imatinib mesylate can indirectly alter brain A ⁇ levels by modulating A ⁇ production peripherally.
- Marker rs4226715 is located on chromosome 7 at 80.138616 Mb, within the modifier locus for that chromosome. Two genes from this interval showed extremely high heritability of expression within the liver: the Ngrn gene, and the Cibl gene.
- the Ngrn gene encodes neugrin, a widely expressed protein of unknown function whose expression increases in some cancers and has been associated with neuroblastoma differentiation (S. Ishigaki, et al., Biochem Biophys Res Commun 279, 526 (2002), S.R.
- calmyrin has a demonstrated interaction with presenilin 2.
- the calmyrin distribution in the brain does not correlate well with either brain presenilin distribution or regions most susceptible to AD pathology, prior studies have considered its potential role in contributing to A ⁇ production in the forebrain, but judged such a role unlikely (M. Blazejczyk, et al., Biochim Biophys Acta 1762, 66 (2006)).
- Calmyrin is, however, highly expressed by the liver (S.M. Stabler, supra).
- One suggested calmyrin activity is as a protein ligand for the inositol 1,4,5-trisphosphate receptor Ca(2+) release channel (C.
- liver calmyrin mRNA expression was extremely high. In every strain that inherited its Cibl genes from the B6 parents, the amount of calmyrin mRNA was higher than the amount observed in strains that inherited their Cibl genes from the D2 parents (Fig. 5A).
- One strain (line 73) appears to be heterozygous at the probe, but expresses D2-like amounts of calmyrin mRNA. This suggests that low calmyrin expression in liver decreases the accumulation of A ⁇ in the brain, and protects mice from its adverse effects. Treatment with a compound that decreases the A ⁇ -potentiating activity of calmyrin should mimic the low expression of the D2 genotype and therefore be protective.
- Neugrin has an inverse correlation (Fig. 4). Abundance of neugrin in liver is correlated with lower A ⁇ accumulation, suggesting that treatment with a compound that increases Neugrin should be protective.
- Marker rs3669981 is located on chromosome 2 at 44.943029 Mb, within the fairly broad modifier locus for that chromosome.
- the Zfhxbl protein is a Smad-interacting transcriptional corepressor involved in Wnt and hedgehog signaling (G. Bassez, et al., Neurobiol Dis 15, 240 (2004); G. Verstappen, et al., Hum MoI Genet 17, 1175 (2008); N.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09761084T PL2365804T3 (en) | 2008-11-13 | 2009-11-13 | Reduction of amyloid-beta load in non-brain tissue |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11445908P | 2008-11-13 | 2008-11-13 | |
US23092609P | 2009-08-03 | 2009-08-03 | |
PCT/US2009/064430 WO2010057020A2 (en) | 2008-11-13 | 2009-11-13 | Modification of amyloid-beta load in non-brain tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2365804A2 true EP2365804A2 (en) | 2011-09-21 |
EP2365804B1 EP2365804B1 (en) | 2015-05-06 |
Family
ID=42165803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09761084.4A Not-in-force EP2365804B1 (en) | 2008-11-13 | 2009-11-13 | Reduction of amyloid-beta load in non-brain tissue |
Country Status (14)
Country | Link |
---|---|
US (2) | US20100120787A1 (en) |
EP (1) | EP2365804B1 (en) |
JP (2) | JP2012508770A (en) |
CN (1) | CN102271669A (en) |
AU (1) | AU2009313851A1 (en) |
CA (1) | CA2742771A1 (en) |
DK (1) | DK2365804T3 (en) |
ES (1) | ES2543987T3 (en) |
HK (1) | HK1162150A1 (en) |
HU (1) | HUE027027T2 (en) |
MX (1) | MX2011004891A (en) |
PL (1) | PL2365804T3 (en) |
PT (1) | PT2365804E (en) |
WO (1) | WO2010057020A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
CN101622275B (en) * | 2007-01-05 | 2013-11-06 | 苏黎世大学 | Method of providing disease-specific binding molecules and targets |
EP2166858A4 (en) | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | Novel heterocycle compounds and uses thereof |
JP5559043B2 (en) * | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | Novel heterocyclic compounds and uses thereof |
ES2544569T3 (en) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein autoantibodies |
WO2012080703A1 (en) * | 2010-12-15 | 2012-06-21 | Cipla Limited | Pharmaceutical composition comprising imatinib |
JP2014528695A (en) | 2011-06-23 | 2014-10-30 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | Anti-alpha synuclein binding molecule |
MX352749B (en) | 2011-11-01 | 2017-12-06 | Modgene Llc | Compositions and methods for reduction of amyloid-beta load. |
CN104334742A (en) | 2012-01-27 | 2015-02-04 | 利兰斯坦福青年大学董事会 | Methods for profiling and quantitating cell-free rna |
US10149855B2 (en) * | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
CN105018484B (en) * | 2015-07-31 | 2017-10-13 | 北京泱深生物信息技术有限公司 | CRTAP genes and its expression product as Alzheimer disease diagnosis and treatment target |
CN105651840B (en) * | 2016-04-01 | 2017-12-26 | 商丘师范学院 | A kind of para-immunity electrochemical sensor for detecting amyloid beta oligomer and preparation method thereof |
SI3672631T1 (en) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0644889A4 (en) * | 1991-12-24 | 1996-01-10 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR MODULATING -g(b)-AMYLOID. |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
DE69426571T2 (en) * | 1993-10-27 | 2001-08-09 | Elan Pharm Inc | TRANSGENIC ANIMALS that house APP alleles with the Swedish mutation |
AU2001257022B2 (en) | 2000-04-13 | 2005-02-03 | Mayo Foundation For Medical Education And Research | Abeta 42 lowering agents |
US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
ES2728168T3 (en) * | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Small RNA molecules that mediate RNA interference |
WO2003057165A2 (en) | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
AT413944B (en) * | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | USE OF OXICAM COMPOUNDS |
AT500483B1 (en) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Kit for prevention or treatment of Alzheimer's disease comprises means for inducing sequestration of amyloid beta in plasma and apheresis apparatus which exhibits an amyloid beta precursor protein receptor |
US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
CA2644240A1 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research, Llc | Compounds for inhibiting beta-amyloid production |
WO2007139120A1 (en) * | 2006-05-30 | 2007-12-06 | Osaka University | AMYLOID-β CLEARANCE ENHANCER |
EP2142515B1 (en) * | 2007-04-18 | 2014-03-26 | Probiodrug AG | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
-
2009
- 2009-11-13 ES ES09761084.4T patent/ES2543987T3/en active Active
- 2009-11-13 CA CA2742771A patent/CA2742771A1/en not_active Abandoned
- 2009-11-13 MX MX2011004891A patent/MX2011004891A/en unknown
- 2009-11-13 AU AU2009313851A patent/AU2009313851A1/en not_active Abandoned
- 2009-11-13 WO PCT/US2009/064430 patent/WO2010057020A2/en active Application Filing
- 2009-11-13 EP EP09761084.4A patent/EP2365804B1/en not_active Not-in-force
- 2009-11-13 JP JP2011536527A patent/JP2012508770A/en active Pending
- 2009-11-13 CN CN2009801543479A patent/CN102271669A/en active Pending
- 2009-11-13 US US12/618,656 patent/US20100120787A1/en not_active Abandoned
- 2009-11-13 HU HUE09761084A patent/HUE027027T2/en unknown
- 2009-11-13 PL PL09761084T patent/PL2365804T3/en unknown
- 2009-11-13 PT PT97610844T patent/PT2365804E/en unknown
- 2009-11-13 DK DK09761084.4T patent/DK2365804T3/en active
-
2012
- 2012-03-19 HK HK12102739.8A patent/HK1162150A1/en not_active IP Right Cessation
-
2015
- 2015-05-13 JP JP2015098095A patent/JP2015172061A/en active Pending
- 2015-11-04 US US14/932,403 patent/US20160287587A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2010057020A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2012508770A (en) | 2012-04-12 |
PL2365804T3 (en) | 2015-10-30 |
WO2010057020A3 (en) | 2010-11-25 |
EP2365804B1 (en) | 2015-05-06 |
HUE027027T2 (en) | 2016-08-29 |
MX2011004891A (en) | 2011-10-06 |
CA2742771A1 (en) | 2010-05-20 |
WO2010057020A2 (en) | 2010-05-20 |
HK1162150A1 (en) | 2012-08-24 |
AU2009313851A1 (en) | 2010-05-20 |
US20160287587A1 (en) | 2016-10-06 |
JP2015172061A (en) | 2015-10-01 |
US20100120787A1 (en) | 2010-05-13 |
ES2543987T3 (en) | 2015-08-26 |
CN102271669A (en) | 2011-12-07 |
DK2365804T3 (en) | 2015-07-27 |
PT2365804E (en) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2365804B1 (en) | Reduction of amyloid-beta load in non-brain tissue | |
Das et al. | A close look at BACE1 inhibitors for Alzheimer’s disease treatment | |
Takahashi et al. | Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network | |
Peters et al. | BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology | |
Wong et al. | 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner | |
Mori et al. | Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice | |
Jacobsen et al. | Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease | |
Teich et al. | Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse | |
Sawa et al. | Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model | |
Oliveros et al. | Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation | |
Giri et al. | Unraveling the genes implicated in Alzheimer's disease | |
US10258623B2 (en) | Compositions and methods for reduction of amyloid-beta load | |
Ahmed et al. | Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development | |
Cummings | Alzheimer’s disease clinical trials: changing the paradigm | |
AU2014200956A1 (en) | Modification of amyloid-beta load in non-brain tissue | |
WO2011011181A1 (en) | Pharmacological chaperones for the treatment of alzheimer's disease | |
Javidnia | Pazopanib reduces tau pathology and restores astrocytes in a novel mouse model of neurodegenerative tauopathy | |
Donahue et al. | Role of SOD and Cathepsin-D in Alzheimer’s Disease Aβ Cascade Models | |
Lobdell et al. | Role of SOD and Cathepsin-D in Alzheimer's Disease Aβ Cascade Models | |
Wilson | Experimental therapy and cognitive outcomes in a rat transgenic model of Alzheimer disease-like amyloid beta neuropathology | |
Adwan et al. | Tolfenamic Acid, a Multi-target Drug Candidate for Alzheimer’s Disease, Downregulates BACE1 via a Transcriptional Mechanism | |
Krosveld | Alzheimer’s Disease. From Target to Drug-Mapping the Developmental Stages. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110614 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20120516 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1162150 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20141128 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 725198 Country of ref document: AT Kind code of ref document: T Effective date: 20150615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009031116 Country of ref document: DE Effective date: 20150618 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20150721 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: TROESCH SCHEIDEGGER WERNER AG, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2543987 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150826 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 725198 Country of ref document: AT Kind code of ref document: T Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20150729 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150806 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20150401580 Country of ref document: GR Effective date: 20150929 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150806 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150906 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009031116 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150506 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1162150 Country of ref document: HK |
|
26N | No opposition filed |
Effective date: 20160209 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E027027 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20161026 Year of fee payment: 8 Ref country code: LU Payment date: 20161129 Year of fee payment: 8 Ref country code: FI Payment date: 20161123 Year of fee payment: 8 Ref country code: HU Payment date: 20161025 Year of fee payment: 8 Ref country code: DK Payment date: 20161123 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20161128 Year of fee payment: 8 Ref country code: PL Payment date: 20161019 Year of fee payment: 8 Ref country code: PT Payment date: 20161020 Year of fee payment: 8 Ref country code: ES Payment date: 20161128 Year of fee payment: 8 Ref country code: BE Payment date: 20161128 Year of fee payment: 8 Ref country code: SE Payment date: 20161125 Year of fee payment: 8 Ref country code: IT Payment date: 20161124 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20161027 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20171130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150506 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180514 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180604 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171114 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171114 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: FP Effective date: 20150805 Ref country code: BE Ref legal event code: MM Effective date: 20171130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181226 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20191127 Year of fee payment: 11 Ref country code: NL Payment date: 20191126 Year of fee payment: 11 Ref country code: IE Payment date: 20191127 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20191125 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20191203 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20191127 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602009031116 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20201201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20201113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201201 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201113 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210601 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201113 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 |